[
    [
        {
            "time": "2021-03-17",
            "original_text": "晚间重要公告2021年3月17日星期三复星医药：YP01001胶囊用于治疗晚期实体瘤获批临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "YP01001胶囊",
                    "晚期实体瘤",
                    "临床试验",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "晚间重要公告2021年3月17日星期三复星医药：YP01001胶囊用于治疗晚期实体瘤获批临床试验",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2026",
            "original_text": "复星医药新药临床试验获批2026年一线肝癌靶向药市场规模或超百亿",
            "features": {
                "keywords": [
                    "复星医药",
                    "新药",
                    "临床试验",
                    "肝癌靶向药",
                    "市场规模"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药新药临床试验获批2026年一线肝癌靶向药市场规模或超百亿",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020",
            "original_text": "2020中国生物药研发实力排行榜TOP5企业管线分析",
            "features": {
                "keywords": [
                    "中国生物药",
                    "研发实力",
                    "排行榜",
                    "TOP5",
                    "企业管线"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "2020中国生物药研发实力排行榜TOP5企业管线分析",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 2
            }
        },
        {
            "time": "2021-03-29",
            "original_text": "复星医药(02196.HK)3月29日举行董事会会议审批年度业绩",
            "features": {
                "keywords": [
                    "复星医药",
                    "董事会会议",
                    "年度业绩"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)3月29日举行董事会会议审批年度业绩",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-03-17",
            "original_text": "渤海证券---医药行业周报：关注一季度业绩同比增长的优质个股【行业研究】",
            "features": {
                "keywords": [
                    "渤海证券",
                    "医药行业",
                    "周报",
                    "一季度业绩",
                    "同比增长",
                    "优质个股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "渤海证券---医药行业周报：关注一季度业绩同比增长的优质个股【行业研究】",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]